With the deep analysis of the above alternatives, it is suggested that the business ought to choose the alternative 3 in order to keep a competitive position in the long run. As the alternative 3 would allow the company to not just present brand-new and innovative items in the market it would likewise decrease the high expenditures on R&D under alternative 2 and increase the profit margins. It would make it possible for the business to increase its share prices as well, as financiers are willing to invest more in companies with considerable R&D costs and boost in the total worth of the business.
Action and implementation Strategy
Method can be executed effectively by establishing certain short term in addition to long term strategies. These strategies could be as follows;
Short Term Plan (0-1 year)
• Under the short-term strategy Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems should perform different activities to implement its NHW strategy efficiently. These activities are as follows;.
• Get the audit of its brand name portfolio done, to take a look at the core selling brands, which produce the majority of its profits.
• Examine the present target market in addition to the market sector which is not include in the business's circle.
• Evaluate the existing financial data to measure the quantity that must be invested in the R&D and acquisitions.
• Evaluate the prospective financiers and their nature, i.e. do they desire long term benefits (capital gain), or the desire early profits (dividend). It would let the business to know that just how much quantity should be spent on R&D.
Mid Term Plan (1-5 years)
• Get those organizations in which the company has prospective experience to deal with. Get most favorable companies with a strong dedication to health, to construct the customer's understandings in the right direction.
• Focus more on acquisitions than R&D to construct the base in the consumer's mind about Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems values and vision and to prevent possible danger of sunk cost.
Long Term Plan (1-10 years)
• Get organizations with health along with taste factor, as the base for the Novartis Gilenya Navigating The Interplay Between Drug Innovation Pricing And Reimbursement In Different Countries Health Care Systems as a company producing healthy products has been built under midterm plan and now the business could move towards taste aspect also to understand the consumers, which focus more on taste rather than health.
• Be more aggressive towards R&D than the acquisitions, as it is the significant time to construct new products.
